The Effect of Cilostazol Combined with Telmisartan on Serum Monocyte Chemotactic Protein-1 and Soluble Intercellu-lar Adhesion Molecule-1 in Early Type 2 Diabetic Nephropathy
JIAO Xiu-min
WU Jin-xiao
CHEN Bin
YUAN Tao
LYU Xiao-feng
Abstract：Objective To observe the effect of cilostazol combined with telmisartan on serum monocyte chemotactic pro-tein-1 (MCP-1) and soluble intercellular adhesion molecule-1 (sICAM-1) in early type 2 diabetic nephropathy. Methods A total of 60 patients with early type 2 diabetic nephropathy were randomly divided into two groups:thirty patients in group A were treated with cilostazol and telmisartan based on routine treatment, while thirty patients in group B were treated with telmisartan a-lone. The levels of 24-h urinary albumin, blood pressure, MCP-1, sICAM-1, alanine aminotransferase, creatinine and glycosy-lated hemoglobin in two groups were compared before treatment and 4 weeks after treatment. Results The levels of 24-h urinary albumin, MCP-1 and sICAM-1 were significantly decreased in both groups after treatment for four weeks, and the differences were significant (P<0. 05). After treatment, the levels of 24-h urinary albumin, MCP-1 and sICAM-1 in group A were obvious-ly lower than those in group B (P<0. 05). Conclusion Cilostazol combined with telmisartan can significantly decrease the uri-nary albumin level in the patients with early type 2 diabetes nephropathy, it can protect the kidney, and delay the progression of early diabetic nephropathy. It is relatively safe in clinical application.
Keywords：Diabetic nephropathiesCilostazolTelmisartanMonocyte chemotactic protein-1Soluble intercellular ad-hesion molecule-1
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 99-101 )